Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Investment in innovation has declined, despite huge profits for pharma – disproving the innovation link

Galvani, et.al., 2020 Alison P. Galvani, PhD,1,* Alyssa S. Parpia, MPH,1 Eric M. Foster,1 Burton H. Singer, PhD,2 and Meagan C. Fitzpatrick, PhD1,3Lancet. 2020 Feb 15; 395(10223): 524–533. Improving the Prognosis of Healthcare in the United States doi: 10.1016/S0140-6736(19)33019-3https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572548/

Concerns have been expressed that reduced profits for pharmaceutical corporations would dampen biomedical innovation.50 However, the observed decline in scientific investmentwhich has accompanied consistently sizable profit margins for the pharmaceutical industry 52 suggests that the market assumptions underlying these concerns may be imperfect. Nonetheless, given that optimal or achievable prices might be different from those negotiated by the VA, our interactive tool allows the price reduction to vary from 0 to 60%. Even if pharmaceutical prices remained unaffected, the MAA would still reduce overall healthcare system costs (Figure 2).

Sign in to recut, update, or save this card.